Please login to the form below

Not currently logged in
Email:
Password:

Grünenthal's Harald Stock joins OvaScience board

Provides European expertise as fertility company looks to expand beyond US

Harald Stock, OvaScienceInfertility specialist OvaScience has appointed Harald Stock, CEO of German pharma firm Grünenthal, to its board of directors.

Stock, who has served in his position at Grünenthal since 2009, will provide US-based OvaScience with strong working knowledge of the European pharma market as the company looks to expand its global reach.

“The global fertility market is nearly 10 times larger than the US alone, and growing rapidly,” said Dr Michelle Dipp, CEO of OvaScience.

“Harald's expertise and success commercialising products in global healthcare markets will be important to OvaScience as we advance our ex-US strategy.”

Prior to joining Grünenthal, Stock was chairman and managing director of the German DePuy Group, the orthopaedics division of Johnson & Johnson.

He has also spent time with Roche, serving in a variety of senior positions, including senior VP of its  global near patient testing business.

In addition, Stock is a board member of EFPIA and previously represented J&J on the board of BVMed, the body representing the medical technology industry in Germany.

12th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...